Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.15 CHF | +10.11% | +30.57% | +84.65% |
Sales 2024 * | 35.98M 38.72M 35.06M | Sales 2025 * | 25.95M 27.93M 25.29M | Capitalization | 159M 171M 155M |
---|---|---|---|---|---|
Net income 2024 * | 7M 7.53M 6.82M | Net income 2025 * | 4M 4.31M 3.9M | EV / Sales 2024 * | 5.22 x |
Net Debt 2024 * | 29.11M 31.33M 28.37M | Net Debt 2025 * | 2M 2.15M 1.95M | EV / Sales 2025 * | 6.19 x |
P/E ratio 2024 * |
10.9
x | P/E ratio 2025 * |
36.5
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Newron Pharmaceuticals S.p.A.
1 day | +9.99% | ||
1 week | +30.57% | ||
Current month | +17.78% | ||
1 month | +12.98% | ||
3 months | +15.11% | ||
6 months | +87.30% | ||
Current year | +84.65% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 9.15 | +10.11% | 165 480 |
24-05-02 | 8.31 | +1.22% | 164,466 |
24-04-30 | 8.21 | +7.46% | 817,574 |
24-04-29 | 7.64 | +4.95% | 80,142 |
24-04-26 | 7.28 | +8.82% | 59,318 |
Delayed Quote Swiss Exchange, May 03, 2024 at 10:42 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+84.65% | 170M | |
-3.79% | 87.06B | |
+2.76% | 40.25B | |
-17.28% | 31.09B | |
+53.17% | 24.74B | |
-13.83% | 15.91B | |
-9.12% | 11.96B | |
-15.96% | 11.92B | |
-42.56% | 11.61B | |
+4.27% | 8.73B |
- Stock Market
- Equities
- NWRN Stock